Claims for Patent: RE46856

Summary for Patent: RE46856

Title:	Substituted 2,3-dihydroimidazo[1,2-c]quinazoline derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
Abstract:	This invention relates to novel 2,3-dihydroimidazo[1,2-c]quinazoline compounds, pharmaceutical compositions containing such compounds and the use of those compounds or compositions for phosphotidylinositol-3-kinase (PI3K) inhibition and treating diseases associated with phosphotidylinositol-3-kinase (PI3K) activity, in particular treating hyperproliferative and/or angiogenesis disorders, as a sole agent or in combination with other active ingredients.
Inventor(s):	Hentemann; Martin (Carlisle, MA), Wood; Jill (Fort Collins, CO), Scott; William (Guilford, CT), Michels; Martin (Koln, DE), Campbell; Ann-Marie (Monroe, CT), Bullion; Ann-Marie (Milford, CT), Rowley; Bruce R. (New Hope, PA), Redman; Aniko (Durham, NC)
Assignee:	Bayer Intellectual Property GMBH (Monheim, DE)
Application Number:	15/398,916
Patent Claims:	1. A compound having the formula: ##STR00154## or a physiologically acceptable salt, solvate, hydrate or stereoisomer thereof, wherein: R.sup.1 is --(CH.sub.2).sub.n--(CHR.sup.4)--(CH.sub.2).sub.m--N(R.sup.5)(R.sup.5'); R.sup.2 is a heteroaryl optionally substituted with 1, 2 or 3 R.sup.6 groups; R.sup.3 is alkyl or cycloalkyl; R.sup.4 is hydrogen, hydroxy or alkoxy; R.sup.5 and R.sup.5' may be the same or different and are independently, hydrogen, alkyl, cycloalkylalklyl, or alkoxyalkyl or R.sup.5 and R.sup.5' may be taken together with the nitrogen atom to which they are bound to form a 3-7 membered nitrogen containing heterocyclic ring optionally containing at least one additional heteroatom selected from oxygen, nitrogen or sulfur and which may be optionally substituted with 1 or more R.sup.6' groups, or R.sup.4 and R.sup.5 may be taken together with the atoms to which they are bound to form a 5-6 membered nitrogen containing heterocyclic ring optionally containing 1 or more nitrogen, oxygen or sulfur atoms and which may be optionally substituted with 1 or more R.sup.6' groups; each occurrence of R.sup.6 may be the same or different and is independently halogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalklyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclic ring, heterocyclylalkyl, alkyl-OR.sup.7, alkyl-SR.sup.7, alkyl-N(R.sup.7)(R.sup.7'), alkyl-COR.sup.7, --CN, --COOR.sup.7, --CON(R.sup.7)(R.sup.7'), --OR.sup.7, --SR.sup.7, --N(R.sup.7)(R.sup.7'), or --NR.sup.7COR.sup.7 each of which may be optionally substituted with 1 or more R.sup.8 groups; each occurrence of R.sup.6' may be the same or different and is independently alkyl, cycloalkylalklyl, or alkyl-OR.sup.7; each occurrence of R.sup.7 and R.sup.7' may be the same or different and is independently hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalklyl, cycloalkenyl, aryl, arylalkyl, heteroaryl, heterocyclic ring, heterocyclylalkyl, or heteroarylalkyl; each occurrence of R.sup.8 is independently nitro, hydroxy, cyano, formyl, acetyl, halogen, amino, alkyl, alkoxy, alkenyl, alkynyl, cycloalkyl, cycloalkylalklyl, cycloalkenyl, aryl, arylalkyl, heteroaryl, heterocyclic ring, heterocyclylalkyl, or heteroarylalkyl; n is an integer from 1-4 and m is an integer from 0-4 with the proviso that when R.sup.4 and R.sup.5 are taken together with the atoms to which they are bound to form a 3-7 membered nitrogen containing ring, n+m.ltoreq.4. 2. The compound of claim 1, wherein R.sup.2 is a nitrogen containing heteroaryl optionally substituted with 1, 2 or 3 R.sup.6 groups. 3. The compound of claim 1, wherein R.sup.5 and R.sup.5' are independently alkyl. 4. The compound of claim 1, wherein R.sup.5 and R.sup.5' are taken together with the nitrogen atom to which they are bound to form a 5-6 membered nitrogen containing heterocyclic ring containing at least one additional heteroatom selected from oxygen, nitrogen or sulfur and which may be optionally substituted with 1 or more R.sup.6' groups. 5. The compound of claim 1, wherein R.sup.4 is hydroxy. 6. The compound of claim 1, wherein R.sup.4 and R.sup.5 are taken together with the atoms to which they are bound to form a 5-6 membered nitrogen containing heterocyclic ring optionally containing 1 or more nitrogen, oxygen or sulfur atoms and which may be optionally substituted with 1 or more R.sup.6' groups. 7. The compound of claim 1, wherein R.sup.3 is methyl. 8. The compound of claim 1, wherein R.sup.2 is pyridine, pyridazine, pyrimidine, pyrazine, pyrole, oxazole, thiazole, furan or thiophene, in each case unsubstituted or substituted with 1, 2 or 3 R.sup.6 groups. 9. The compound of claim 2, wherein R.sup.2 is pyridine, pyridazine, pyrimidine, pyrazine, pyrole, oxazole or thiazole, in each case unsubstituted or substituted with 1, 2 or 3 R.sup.6 groups. 10. The compound of claim 1, having the formula: ##STR00155## 11. The compound of claim 10, wherein R.sup.2 is pyridine, pyridazine, pyrimidine, pyrazine, pyrole, oxazole, thiazole, furan or thiophene, in each case unsubstituted or substituted with 1, 2 or 3 R.sup.6 groups. 12. The compound of claim 11, wherein R.sup.2 is pyridine, pyridazine, pyrimidine, pyrazine, pyrole, oxazole or thiazole, in each case unsubstituted or substituted with 1, 2 or 3 R.sup.6 groups. 13. The compound of claim 1 having the formula: ##STR00156## 14. The compound of claim 13, wherein R.sup.2 is pyridine, pyridazine, pyrimidine, pyrazine, pyrole, oxazole, thiazole, furan or thiophene, in each case unsubstituted or substituted with 1, 2 or 3 R.sup.6 groups. 15. The compound of claim 14, wherein R.sup.2 is pyridine, pyridazine, pyrimidine, pyrazine, pyrole, oxazole or thiazole, in each case unsubstituted or substituted with 1, 2 or 3 R.sup.6 groups. 16. The compound of claim 1 having the formula: ##STR00157## 17. The compound of claim 16, wherein R.sup.2 is pyridine, pyridazine, pyrimidine, pyrazine, pyrole, oxazole, thiazole, furan or thiophene, in each case unsubstituted or substituted with 1, 2 or 3 R.sup.6 groups. 18. The compound of claim 17, wherein R.sup.2 is pyridine, pyridazine, pyrimidine, pyrazine, pyrole, oxazole or thiazole, in each case unsubstituted or substituted with 1, 2 or 3 R.sup.6 groups. 19. The compound of claim 1 having the formula: ##STR00158## 20. The compound of claim 19, wherein R.sup.2 is pyridine, pyridazine, pyrimidine, pyrazine, pyrole, oxazole, thiazole, furan or thiophene, in each case unsubstituted or substituted with 1, 2 or 3 R.sup.6 groups. 21. The compound of claim 20, wherein R.sup.2 is pyridine, pyridazine, pyrimidine, pyrazine, pyrole, oxazole or thiazole, in each case unsubstituted or substituted with 1, 2 or 3 R.sup.6 groups. 22. The compound of claim 19.Iadd., .Iaddend.wherein R.sup.5' is alkyl. 23. The compound of claim 1 having the formula: ##STR00159## 24. The compound of claim 23, wherein R.sup.2 is pyridine, pyridazine, pyrimidine, pyrazine, pyrole, oxazole, thiazole, furan or thiophene, in each case unsubstituted or substituted with 1, 2 or 3 R.sup.6 groups. 25. The compound of claim 24, wherein R.sup.2 is pyridine, pyridazine, pyrimidine, pyrazine, pyrole, oxazole or thiazole, in each case unsubstituted or substituted with 1, 2 or 3 R.sup.6 groups. 26. The compound of claim 23.Iadd., .Iaddend.wherein R.sup.5' is alkyl. 27. The compound according to claim 1, wherein said compound is selected from: N-[7-methoxy-8-(3-morpholin-4-ylpropoxy)-2,3-dihydroimidazo[1,2-c]q- uinazolin-5-yl]pyrimidine-5-carboxamide; N-(8-{3-[(2R,6S)-2,6-dimethylmorpholin-4-yl]propoxy}-7-methoxy-2,3-dihydr- oimidazo[1,2-c]quinazolin-5-yl)nicotinamide; N-(8-{3-[(2R,6S)-2,6-dimethylmorpholin-4-yl]propoxy}-7-methoxy-2,3-dihydr- oimidazo[1,2-c]quinazolin-5-yl)-2,4-dimethyl-1,3-thiazole-5-carboxamide; 2-amino-N-[7-methoxy-8-(3-morpholin-4-ylpropoxy)-2,3-dihydroimidazo[1,2-c- ]quinazolin-5-yl]-1,3-thiazole-5-carboxamide; 2-amino-N-[7-methoxy-8-(3-morpholin-4-ylpropoxy)-2,3-dihydroimidazo[1,2-c- ]quinazolin-5-yl]isonicotinamide; 2-amino-N-[7-methoxy-8-(3-morpholin-4-ylpropoxy)-2,3-dihydroimidazo[1,2-c- ]quinazolin-5-yl]-4-methyl-1,3-thiazole-5-carboxamide; 2-amino-N-[7-methoxy-8-(3-morpholin-4-ylpropoxy)-2,3-dihydroimidazo[1,2-c- ]quinazolin-5-yl]-4-propylpyrimidine-5-carboxamide; N-{8-[2-(4-ethylmorpholin-2-yl)ethoxy]-7-methoxy-2,3-dihydroimidazo[1,2-c- ]quinazolin-5-yl}nicotinamide; N-{8-[2-(dimethylamino)ethoxy]-7-methoxy-2,3-dihydroimidazo[1,2-c]quinazo- lin-5-yl}pyrimidine-5-carboxamide; N-(8-{3-[2-(hydroxymethyl)morpholin-4-yl]propoxy}-7-methoxy-2,3-dihydroim- idazo[1,2-c]quinazolin-5-yl)nicotinamide; N-(8-{3-[2-(hydroxymethyl)morpholin-4-yl]propoxy}-7-methoxy-2,3-dihydroim- idazo[1,2-c]quinazolin-5-yl)nicotinamide; N-{8-[3-(dimethylamino)propoxy]-7-methoxy-2,3-dihydroimidazo[1,2-c]quinaz- olin-5-yl}nicotinamide 1-oxide; 2-amino-N-[7-methoxy-8-(3-morpholin-4-ylpropoxy)-2,3-dihydroimidazo[1,2-c- ]quinazolin-5-yl]pyrimidine-5-carboxamide; N-[7-methoxy-8-(3-morpholin-4-ylpropoxy)-2,3-dihydroimidazo[1,2-c]quinazo- lin-5-yl]-6-(2-pyrrolidin-1-ylethyl)nicotinamide; 6-(cyclopentylamino)-N-[7-methoxy-8-(3-morpholin-4-ylpropoxy)-2,3-dihydro- imidazo[1,2-c]quinazolin-5-yl]nicotinamide; N-[8-(2-hydroxy-3-morpholin-4-ylpropoxy)-7-methoxy-2,3-dihydroimidazo[1,2- -c]quinazolin-5-yl]nicotinamide; N-{7-methoxy-8-[3-(3-methylmorpholin-4-yl)propoxy]-2,3-dihydroimidazo[1,2- -c]quinazolin-5-yl}nicotinamide; N-(8-{3-[2-(hydroxymethyl)morpholin-4-yl]propoxy}-7-methoxy-2,3-dihydroim- idazo[1,2-c]quinazolin-5-yl)nicotinamide; N-(8-{2-[4-(cyclobutylmethyl)morpholin-2-yl]ethoxy}-7-methoxy-2,3-dihydro- imidazo[1,2-c]quinazolin-5-yl)nicotinamide; N-(7-methoxy-8-{2-[4-(2-methoxyethyl)morpholin-2-yl]ethoxy}-2,3-dihydroim- idazo[1,2-c]quinazolin-5-yl)nicotinamide; N-{8-[(4-ethylmorpholin-2-yl)methoxy]-7-methoxy-2,3-dihydroimidazo[1,2-c]- quinazolin-5-yl}nicotinamide; N-(7-methoxy-8-{[4-(2-methoxyethyl)morpholin-2-yl]methoxy}-2,3-dihydroimi- dazo[1,2-c]quinazolin-5-yl)nicotinamide; N-{7-methoxy-8-[(4-methylmorpholin-2-yl)methoxy]-2,3-dihydroimidazo[1,2-c- ]quinazolin-5-yl}nicotinamide; N-[7-methoxy-8-(3-morpholin-4-ylpropoxy)-2,3-dihydroimidazo[1,2-c]quinazo- lin-5-yl]pyrimidine-4-carboxamide; 2-amino-N-[7-methoxy-8-(3-morpholin-4-ylpropoxy)-2,3-dihydroimidazo[1,2-c- ]quinazolin-5-yl]pyrimidine-4-carboxamide; N-[7-methoxy-8-(3-morpholin-4-ylpropoxy)-2,3-dihydroimidazo[1,2-c]quinazo- lin-5-yl]-1-methyl-1H-imidazole-4-carboxamide; rel-N-(8-{3-[(2R,6S)-2,6-dimethylmorpholin-4-yl]propoxy}-7-methoxy-2,3-di- hydroimidazo[1,2-c]quinazolin-5-yl)pyrimidine-5-carboxamide; rel-N-(8-{3-[(2R,6S)-2,6-dimethylmorpholin-4-yl]propoxy}-7-methoxy-2,3-di- hydroimidazo[1,2-c]quinazolin-5-yl)-6-methylnicotinamide; rel-6-acetamido-N-(8-{3-[(2R,6S)-2,6-dimethylmorpholin-4-yl]propoxy}-7-me- thoxy-2,3-dihydroimidazo[1,2-c]quinazolin-5-yl)nicotinamide; N-[7-methoxy-8-(3-morpholin-4-ylpropoxy)-2,3-dihydroimidazo[1,2-c]quinazo- lin-5-yl]-1-methyl-1H-imidazole-5-carboxamide; 6-amino-N-[7-methoxy-8-(3-morpholin-4-ylpropoxy)-2,3-dihydroimidazo[1,2-c- ]quinazolin-5-yl]-2-methylnicotinamide; 2-amino-N-[7-methoxy-8-(3-morpholin-4-ylpropoxy)-2,3-dihydroimidazo[1,2-c- ]quinazolin-5-yl]-4-methylpyrimidine-5-carboxamide; 6-amino-5-bromo-N-[7-methoxy-8-(3-morpholin-4-ylpropoxy)-2,3-dihydroimida- zo[1,2-c]quinazolin-5-yl]nicotinamide; 2-amino-N-[7-methoxy-8-(3-morpholin-4-ylpropoxy)-2,3-dihydroimidazo[1,2-c- ]quinazolin-5-yl]-1,3-oxazole-5-carboxamide; N-[7-methoxy-8-(morpholin-2-ylmethoxy)-2,3-dihydroimidazo[1,2-c]quinazoli- n-5-yl]nicotinamide; 2-{[2-(dimethylamino)ethyl]amino}-N-{8-[3-(dimethylamino)propoxy]-7-metho- xy-2,3-dihydroimidazo[1,2-c]quinazolin-5-yl}pyrimidine-5-carboxamide; 2-amino-N-{8-[3-(dimethylamino)propoxy]-7-methoxy-2,3-dihydroimidazo[1,2-- c]quinazolin-5-yl}-1,3-thiazole-5-carboxamide; rel-2-amino-N-(8-{3-[(2R,6S)-2,6-dimethylmorpholin-4-yl]propoxy}-7-methox- y-2,3-dihydroimidazo[1,2-c]quinazolin-5-yl)pyrimidine-5-carboxamide; rel-6-amino-N-(8-{3-[(2R,6S)-2,6-dimethylmorpholin-4-yl]propoxy}-7-methox- y-2,3-dihydroimidazo[1,2-c]quinazolin-5-yl)nicotinamide; 2-[(2-hydroxyethyl)amino]-N-[7-methoxy-8-(3-morpholin-4-ylpropoxy)-2,3-di- hydroimidazo[1,2-c]quinazolin-5-yl]pyrimidine-5-carboxamide; N-[7-methoxy-8-(3-morpholin-4-ylpropoxy)-2,3-dihydroimidazo[1,2-c]quinazo- lin-5-yl]-2-[(3-methoxypropyl)amino]pyrimidine-5-carboxamide; 2-amino-N-{8-[3-(dimethylamino)propoxy]-7-methoxy-2,3-dihydroimidazo[1,2-- c]quinazolin-5-yl}pyrimidine-5-carboxamide; N-[7-methoxy-8-(3-morpholin-4-ylpropoxy)-2,3-dihydroimidazo[1,2-c]quinazo- lin-5-yl]-2-[(3-morpholin-4-ylpropyl)amino]pyrimidine-5-carboxamide; 2-[(2-methoxyethyl)amino]-N-[7-methoxy-8-(3-morpholin-4-ylpropoxy)-2,3-di- hydroimidazo[1,2-c]quinazolin-5-yl]pyrimidine-5-carboxamide; 2-{[2-(dimethylamino)ethyl]amino}-N-[7-methoxy-8-(3-morpholin-4-ylpropoxy- )-2,3-dihydroimidazo[1,2-c]quinazolin-5-yl]pyrimidine-5-carboxamide; 6-amino-N-{8-[3-(dimethylamino)propoxy]-7-methoxy-2,3-dihydroimidazo[1,2-- c]quinazolin-5-yl}nicotinamide; N-[7-methoxy-8-(3-morpholin-4-ylpropoxy)-2,3-dihydroimidazo[1,2-c]quinazo- lin-5-yl]-2-pyrrolidin-1-ylpyrimidine-5-carboxamide; N-[7-methoxy-8-(3-morpholin-4-ylpropoxy)-2,3-dihydroimidazo[1,2-c]quinazo- lin-5-yl]-2-(4-methylpiperazin-1-yl)pyrimidine-5-carboxamide; N-[7-methoxy-8-(3-morpholin-4-ylpropoxy)-2,3-dihydroimidazo[1,2-c]quinazo- lin-5-yl]-2-morpholin-4-ylpyrimidine-5-carboxamide; N-[7-methoxy-8-(3-morpholin-4-ylpropoxy)-2,3-dihydroimidazo[1,2-c]quinazo- lin-5-yl]-6-piperazin-1-ylnicotinamide hydrochloride; 6-[(3S)-3-aminopyrrolidin-1-yl]-N-[7-methoxy-8-(3-morpholin-4-ylpropoxy)-- 2,3-dihydroimidazo[1,2-c]quinazolin-5-yl]nicotinamide hydrochloride hydrate; 6-[(3R)-3-aminopyrrolidin-1-yl]-N-[7-methoxy-8-(3-morpholin-4-yl- propoxy)-2,3-dihydroimidazo[1,2-c]quinazolin-5-yl]nicotinamide hydrochloride; 6-[(4-fluorobenzyl)amino]-N-[7-methoxy-8-(3-morpholin-4-ylpropoxy)-2,3-di- hydroimidazo[1,2-c]quinazolin-5-yl]nicotinamide; 6-[(2-furylmethyl)amino]-N-[7-methoxy-8-(3-morpholin-4-ylpropoxy)-2,3-dih- ydroimidazo[1,2-c]quinazolin-5-yl]nicotinamide; 6-[(2-methoxyethyl)amino]-N-[7-methoxy-8-(3-morpholin-4-ylpropoxy)-2,3-di- hydroimidazo[1,2-c]quinazolin-5-yl]nicotinamide; N-[7-methoxy-8-(3-morpholin-4-ylpropoxy)-2,3-dihydroimidazo[1,2-c]quinazo- lin-5-yl]-6-(1H-pyrrol-1-yl)nicotinamide; N-[7-methoxy-8-(3-morpholin-4-ylpropoxy)-2,3-dihydroimidazo[1,2-c]quinazo- lin-5-yl]-6-morpholin-4-ylnicotinamide; N-{7-methoxy-8-[3-(methylamino)propoxy]-2,3-dihydroimidazo[1,2-c]quinazol- in-5-yl}nicotinamide; 6-[(2,2-dimethylpropanoyl)amino]-N-[7-methoxy-8-(3-morpholin-4-ylpropoxy)- -2,3-dihydroimidazo[1,2-c]quinazolin-5-yl]nicotinamide; 6-[(cyclopropylcarbonyl)amino]-N-[7-methoxy-8-(3-morpholin-4-ylpropoxy)-2- ,3-dihydroimidazo[1,2-c]quinazolin-5-yl]nicotinamide N-[7-methoxy-8-(3-morpholin-4-ylpropoxy)-2,3-dihydroimidazo[1,2-c]quinazo- lin-5-yl]-6-(2,2,2-trifluoroethoxy)nicotinamide; N-[7-methoxy-8-(3-morpholin-4-ylpropoxy)-2,3-dihydroimidazo[1,2-c]quinazo- lin-5-yl]-6-(trifluoromethyl)nicotinamide; 6-(isobutyrylamino)-N-[7-methoxy-8-(3-morpholin-4-ylpropoxy)-2,3-dihydroi- midazo[1,2-c]quinazolin-5-yl]nicotinamide; N-{7-methoxy-8-[3-(4-methylpiperazin-1-yl)propoxy]-2,3-dihydroimidazo[1,2- -c]quinazolin-5-yl}nicotinamide; N-[7-methoxy-8-(3-morpholin-4-ylpropoxy)-2,3-dihydroimidazo[1,2-c]quinazo- lin-5-yl]-2-{[(methylamino)carbonyl]amino}-1,3-thiazole-4-carboxamide; N-[7-methoxy-8-(3-morpholin-4-ylpropoxy)-2,3-dihydroimidazo[1,2-c]quinazo- lin-5-yl]-6-{[(methylamino)carbonyl]amino}nicotinamide; N-[7-methoxy-8-(3-morpholin-4-ylpropoxy)-2,3-dihydroimidazo[1,2-c]quinazo- lin-5-yl]-2-(methylamino)-1,3-thiazole-4-carboxamide; N-[7-methoxy-8-(2-morpholin-4-ylethoxy)-2,3-dihydroimidazo[1,2-c]quinazol- in-5-yl]nicotinamide; N-{8-[2-(dimethylamino)ethoxy]-7-methoxy-2,3-dihydroimidazo[1,2-c]quinazo- lin-5-yl}-2,4-dimethyl-1,3-thiazole-5-carboxamide; N-{8-[2-(dimethylamino)ethoxy]-7-methoxy-2,3-dihydroimidazo[1,2-c]quinazo- lin-5-yl}-6-methylnicotinamide; 6-{[(isopropylamino)carbonyl]amino}-N-[7-methoxy-8-(3-morpholin-4-ylpropo- xy)-2,3-dihydroimidazo[1,2-c]quinazolin-5-yl]nicotinamide; N-[7-methoxy-8-(3-morpholin-4-ylpropoxy)-2,3-dihydroimidazo[1,2-c]quinazo- lin-5-yl]-6-pyrrolidin-1-ylnicotinamide; 6-(dimethylamino)-N-[7-methoxy-8-(3-morpholin-4-ylpropoxy)-2,3-dihydroimi- dazo[1,2-c]quinazolin-5-yl]nicotinamide; N-[7-methoxy-8-(3-piperidin-1-ylpropoxy)-2,3-dihydroimidazo[1,2-c]quinazo- lin-5-yl]nicotinamide; N-[7-methoxy-8-(2-pyrrolidin-1-ylethoxy)-2,3-dihydroimidazo[1,2-c]quinazo- lin-5-yl]nicotinamide; N-[7-methoxy-8-(2-piperidin-1-ylethoxy)-2,3-dihydroimidazo[1,2-c]quinazol- in-5-yl]nicotinamide; 6-{[(ethylamino)carbonyl]amino}-N-[7-methoxy-8-(3-morpholin-4-ylpropoxy)-- 2,3-dihydroimidazo[1,2-c]quinazolin-5-yl]nicotinamide; 6-fluoro-N-[7-methoxy-8-(3-morpholin-4-ylpropoxy)-2,3-dihydroimidazo[1,2-- c]quinazolin-5-yl]nicotinamide; 2-amino-N-[7-methoxy-8-(3-morpholin-4-ylpropoxy)-2,3-dihydroimidazo[1,2-c- ]quinazolin-5-yl]-1,3-oxazole-4-carboxamide; 2-(ethylamino)-N-[7-methoxy-8-(3-morpholin-4-ylpropoxy)-2,3-dihydroimidaz- o[1,2-c]quinazolin-5-yl]-1,3-thiazole-4-carboxamide; N-[7-methoxy-8-(3-morpholin-4-ylpropoxy)-2,3-dihydroimidazo[1,2-c]quinazo- lin-5-yl]pyrazine-2-carboxamide; N-[8-(2-aminoethoxy)-7-methoxy-2,3-dihydroimidazo[1,2-c]quinazolin-5-yl]n- icotinamide; 6-amino-N-[7-methoxy-8-(3-morpholin-4-ylpropoxy)-2,3-dihydroimidazo[1,2-c- ]quinazolin-5-yl]nicotinamide; N-[7-methoxy-8-(3-morpholin-4-ylpropoxy)-2,3-dihydroimidazo[1,2-c]quinazo- lin-5-yl]isonicotinamide; N-{8-[3-(diethylamino)propoxy]-7-methoxy-2,3-dihydroimidazo[1,2-c]quinazo- lin-5-yl}nicotinamide; N-{8-[2-(diisopropylamino)ethoxy]-7-methoxy-2,3-dihydroimidazo[1,2-c]quin- azolin-5-yl}nicotinamide; N-{8-[2-(diethylamino)ethoxy]-7-methoxy-2,3-dihydroimidazo[1,2-c]quinazol- in-5-yl}nicotinamide; N-{8-[3-(dimethylamino)propoxy]-7-methoxy-2,3-dihydroimidazo[1,2-c]quinaz- olin-5-yl}nicotinamide; N-{8-[2-(dimethylamino)ethoxy]-7-methoxy-2,3-dihydroimidazo[1,2-c]quinazo- lin-5-yl}nicotinamide; N-[7-methoxy-8-(3-morpholin-4-ylpropoxy)-2,3-dihydroimidazo[1,2-c]quinazo- lin-5-yl]-2-(methylamino)pyrimidine-5-carboxamide; N-[7-methoxy-8-(3-morpholin-4-ylpropoxy)-2,3-dihydroimidazo[1,2-c]quinazo- lin-5-yl]-2-(methylthio)pyrimidine-5-carboxamide; N-[8-(3-aminopropoxy)-7-methoxy-2,3-dihydroimidazo[1,2-c]quinazolin-5-yl]- nicotinamide trifluoroacetate; N-[7-methoxy-8-(3-morpholin-4-ylpropoxy)-2,3-dihydroimidazo[1,2-c]quinazo- lin-5-yl]thiophene-2-carboxamide; N-[7-methoxy-8-(3-morpholin-4-ylpropoxy)-2,3-dihydroimidazo[1,2-c]quinazo- lin-5-yl]-2,4-dimethyl-1,3-thiazole-5-carboxamide; 2-methoxy-N-[7-methoxy-8-(3-morpholin-4-ylpropoxy)-2,3-dihydroimidazo[1,2- -c]quinazolin-5-yl]pyrimidine-5-carboxamide; N-[7-methoxy-8-(3-morpholin-4-ylpropoxy)-2,3-dihydroimidazo[1,2-c]quinazo- lin-5-yl]-3-furamide; N-[7-methoxy-8-(3-morpholin-4-ylpropoxy)-2,3-dihydroimidazo[1,2-c]quinazo- lin-5-yl]thiophene-3-carboxamide; N-[7-methoxy-8-(3-morpholin-4-ylpropoxy)-2,3-dihydroimidazo[1,2-c]quinazo- lin-5-yl]-2-methyl-1,3-thiazole-4-carboxamide; 6-methoxy-N-[7-methoxy-8-(3-morpholin-4-ylpropoxy)-2,3-dihydroimidazo[1,2- -c]quinazolin-5-yl]nicotinamide; 5-methoxy-N-[7-methoxy-8-(3-morpholin-4-ylpropoxy)-2,3-dihydroimidazo[1,2- -c]quinazolin-5-yl]nicotinamide; N-[7-methoxy-8-(3-morpholin-4-ylpropoxy)-2,3-dihydroimidazo[1,2-c]quinazo- lin-5-yl]-6-methylnicotinamide; 6-(acetylamino)-N-[7-methoxy-8-(3-morpholin-4-ylpropoxy)-2,3-dihydroimida- zo[1,2-c]quinazolin-5-yl]nicotinamide; N-[7-methoxy-8-(3-morpholin-4-ylpropoxy)-2,3-dihydroimidazo[1,2-c]quinazo- lin-5-yl]nicotinamide; and physiologically acceptable salts, solvates, hydrates, and stereoisomers thereof. 28. The compound according to claim 1, wherein said compound is selected from: N-[7-methoxy-8-(3-morpholin-4-ylpropoxy)-2,3-dihydroimidazo[1,2-c]q- uinazolin-5-yl]nicotinamide; N-[7-methoxy-8-(3-morpholin-4-ylpropoxy)-2,3-dihydroimidazo[1,2-c]quinazo- lin-5-yl]-6-methylnicotinamide; 5-methoxy-N-[7-methoxy-8-(3-morpholin-4-ylpropoxy)-2,3-dihydroimidazo[1,2- -c]quinazolin-5-yl]nicotinamide; N-[7-methoxy-8-(3-morpholin-4-ylpropoxy)-2,3-dihydroimidazo[1,2-c]quinazo- lin-5-yl]-2,4-dimethyl-1,3-thiazole-5-carboxamide; N-{8-[2-(dimethylamino)ethoxy]-7-methoxy-2,3-dihydroimidazo[1,2-c]quinazo- lin-5-yl}nicotinamide; N-{8-[3-(dimethylamino)propoxy]-7-methoxy-2,3-dihydroimidazo[1,2-c]quinaz- olin-5-yl}nicotinamide; 6-{[(isopropylamino)carbonyl]amino}-N-[7-methoxy-8-(3-morpholin-4-ylpropo- xy)-2,3-dihydroimidazo[1,2-c]quinazolin-5-yl]nicotinamide; N-{8-[2-(dimethylamino)ethoxy]-7-methoxy-2,3-dihydroimidazo[1,2-c]quinazo- lin-5-yl}-2,4-dimethyl-1,3-thiazole-5-carboxamide; N-[7-methoxy-8-(2-morpholin-4-ylethoxy)-2,3-dihydroimidazo[1,2-c]quinazol- in-5-yl]nicotinamide; rel-6-amino-N-(8-{3-[(2R,6S)-2,6-dimethylmorpholin-4-yl]propoxy}-7-methox- y-2,3-dihydroimidazo[1,2-c]quinazolin-5-yl)nicotinamide; rel-2-amino-N-(8-{3-[(2R,6S)-2,6-dimethylmorpholin-4-yl]propoxy}-7-methox- y-2,3-dihydroimidazo[1,2-c]quinazolin-5-yl)pyrimidine-5-carboxamide; 2-amino-N-[7-methoxy-8-(3-morpholin-4-ylpropoxy)-2,3-dihydroimidazo[1,2-c- ]quinazolin-5-yl]pyrimidine-5-carboxamide; N-{8-[2-(dimethylamino)ethoxy]-7-methoxy-2,3-dihydroimidazo[1,2-c]quinazo- lin-5-yl}pyrimidine-5-carboxamide; N-[7-methoxy-8-(3-morpholin-4-ylpropoxy)-2,3-dihydroimidazo[1,2-c]quinazo- lin-5-yl]pyrimidine-5-carboxamide; and physiologically acceptable salts, solvates, hydrates and stereoisomers thereof. 29. A pharmaceutical composition comprising a compound according to claim 1 and a pharmaceutically acceptable diluent or carrier. 30. The pharmaceutical composition of claim 29, wherein the compound is present in a therapeutically effective amount. 31. The pharmaceutical composition of claim 29, further comprising at least one further active compound. 32. The pharmaceutical composition of claim 29, wherein the further active compound is an anti-hyper-proliferative, anti-inflammatory, analgesic, immunoregulatory, diuretic, anti-arrhythmic, anti-hypercholesterolemic, anti-diabetic, anti-dyslipidemia, anti-diabetic or antiviral agent. 33. The pharmaceutical composition of claim 32, wherein the further active compound is gemcitabine, paclitaxel, cisplatin, carboplatin, sodium butyrate, 5-FU, doxirubicin, tamoxifen, etoposide, trastumazab, gefitinib, intron A, rapamycin, 17-AAG, U0126, insulin, an insulin derivative, a PPAR ligand, a sulfonylurea drug, an .alpha.-glucosidase inhibitor, a biguanide, a PTP-1B inhibitor, a DPP-IV inhibitor, a 11-beta-HSD inhibitor, GLP-1, a GLP-1 derivative, GIP, a GIP derivative, PACAP, a PACAP derivative, secretin, secretin derivative, aldesleukin, alendronic acid, alfaferone, alitretinoin, allopurinol, aloprim, aloxi, altretamine, aminoglutethimide, amifostine, amrubicin, amsacrine, anastrozole, anzmet, aranesp, arglabin, arsenic trioxide, aromasin, 5-azacytidine, azathioprine, BCG or tice BCG, bestatin, betamethasone acetate, betamethasone sodium phosphate, bexarotene, bleomycin sulfate, broxuridine, bortezomib, busulfan, calcitonin, campath, capecitabine, carboplatin, casodex, cefesone, celmoleukin, cerubidine, chlorambucil, cisplatin, cladribine, .[.cladribine,.]. clodronic acid, cyclophosphamide, cytarabine, dacarbazine, dactinomycin, DaunoXome, decadron, decadron phosphate, delestrogen, denileukin diftitox, depo-medrol, deslorelin, dexrazoxane, diethylstilbestrol, diflucan, docetaxel, doxifluridine, doxorubicin, dronabinol, DW-166HC, eligard, elitek, ellence, emend, epirubicin, epoetin alfa, epogen, eptaplatin, ergamisol, estrace, estradiol, estramustine phosphate sodium, ethinyl estradiol, ethyol, etidronic acid, etopophos, etoposide, fadrozole, farston, filgrastim, finasteride, fligrastim, floxuridine, fluconazole, fludarabine, 5-fluorodeoxyuridine monophosphate, 5-fluorouracil (5-FU), fluoxymesterone, flutamide, formestane, fosteabine, fotemustine, fulvestrant, gammagard, gemcitabine, gemtuzumab, gleevec, gliadel, goserelin, granisetron HCl, histrelin, hycamtin, hydrocortone, eyrthrohydroxynonyladenine, hydroxyurea, ibritumomab tiuxetan, idarubicin, ifosfamide, interferon alpha, interferon-alpha 2, interferon alfa-2A, interferon alfa-2B, interferon alfa-n1, interferon alfa-n3, interferon beta, interferon gamma-1a, interleukin-2, intron A, iressa, irinotecan, kytril, lentinan sulphate, letrozole, leucovorin, leuprolide, leuprolide acetate, levamisole, levofolinic acid calcium salt, levothroid, levoxyl, lomustine, lonidamine, marinol, mechlorethamine, mecobalamin, medroxyprogesterone acetate, megestrol acetate, melphalan, menest, 6-mercaptopurine, Mesna, methotrexate, metvix, miltefosine, minocycline, mitomycin C, mitotane, mitoxantrone, Modrenal, Myocet, nedaplatin, neulasta, neumega, neupogen, nilutamide, nolvadex, NSC-631570, OCT-43, octreotide, ondansetron HCl, orapred, oxaliplatin, paclitaxel, pediapred, pegaspargase, Pegasys, pentostatin, picibanil, pilocarpine HCl, pirarubicin, plicamycin, porfimer sodium, prednimustine, prednisolone, prednisone, premarin, procarbazine, procrit, raltitrexed, rebif, rhenium-186 etidronate, rituximab, roferon-A, romurtide, salagen, sandostatin, sargramostim, semustine, sizofuran, sobuzoxane, solumedrol, sparfosic acid, stem-cell therapy, streptozocin, strontium-89 chloride, synthroid, tamoxifen, tamsulosin, tasonermin, tastolactone, taxotere, teceleukin, temozolomide, teniposide, testosterone propionate, testred, thioguanine, thiotepa, thyrotropin, tiludronic acid, topotecan, toremifene, tositumomab, trastuzumab, treosulfan, tretinoin, trexall, trimethylmelamine, trimetrexate, triptorelin acetate, triptorelin pamoate, UFT, uridine, valrubicin, vesnarinone, vinblastine, vincristine, vindesine, vinorelbine, virulizin, zinecard, zinostatin stimalamer, zofran, ABI-007, acolbifene, actimmune, affinitak, aminopterin, arzoxifene, asoprisnil, atamestane, atrasentan, BAY 43-9006 (sorafenib), avastin, CCI-779, CDC-501, celebrex, cetuximab, crisnatol, cyproterone acetate, decitabine, DN-101, doxorubicin-MTC, dSLIM, dutasteride, edotecarin, eflornithine, exatecan, fenretinide, histamine dihydrochloride, histrelin hydrogel implant, holmium-166 DOTMP, ibandronic acid, interferon gamma, intron-PEG, ixabepilone, keyhole limpet hemocyanin, L-651582, lanreotide, lasofoxifene, libra, lonafarnib, miproxifene, minodronate, MS-209, liposomal MTP-PE, MX-6, nafarelin, nemorubicin, neovastat, nolatrexed, oblimersen, onco-TCS, osidem, paclitaxel polyglutamate, pamidronate disodium, PN-401, QS-21, quazepam, R-1549, raloxifene, ranpirnase, 13-cis-retinoic acid, satraplatin, seocalcitol, T-138067, tarceva, taxoprexin, thymosin alpha 1, tiazofurine, tipifarnib, tirapazamine, TLK-286, toremifene, TransMID-107R, valspodar, vapreotide, vatalanib, verteporfin, vinflunine, Z-100, zoledronic acid or combinations thereof. 34. A packaged pharmaceutical composition comprising a container, the pharmaceutical composition of claim 29 and instructions for using the pharmaceutical composition to treat a disease or condition in a mammal. 35. A method of inhibiting phosphotidylinositol-3-kinase in cells comprising contacting a cell with one or more compounds of claim 1. 36. A method of treating a disorder mediated by phosphotidylinositol-3-kinase inhibition in a mammal comprising administering to a mammal in need thereof, a therapeutically effective amount of one or more compounds of claim 1. 37. The method of claim 36, wherein the disorder mediated by phosphotidylinosito-3-kinase is an angiogenic disorder, an inflammatory disorder, an autoimmune disorder, a cardiovascular disorder, a neurodegenerative disorder, a metabolic disorder, a nociceptive disorder, an ophthalmic disorder, a pulmonary disorder, or a renal disorder. 38. The method of claim 37, wherein the cardiovascular disorder is thrombosis, pulmonary hypertension, cardiac hypertrophy, atherosclerosis or heart failure. 39. The method of claim 37, wherein the inflammatory disorder is COPD. 40. The method of claim 37, wherein the angiogenic disorder .Iadd.is .Iaddend.diabetic retinopathy, ischemic retinal-vein occlusion, retinopathy of prematurity, macular degeneration, neovascular glaucoma, psoriasis, retrolental fibroplasias, angiofibroma, inflammation, rheumatoid arthritis, restenosis, in-stent restenosis, or vascular graft restenosis. 41. A method of treating a hyperproliferative disorder mediated by phosphotidylinositol-3-kinase in a mammal comprising administering to a mammal in need thereof, a therapeutically effective amount of one or more compounds of claim 1. 42. The method of claim 41, wherein the hyperproliferative disorder is cancer. 43. The method of claim 42, wherein the cancer is a cancer of the breast, respiratory tract, brain, reproductive organs, digestive tract, urinary tract, eye, liver, skin, head and neck, thyroid, parathyroid or a distant metastasis of a solid tumor. 44. The method of claim 42.Iadd., .Iaddend.wherein the cancer is a lymphoma, sarcoma, or leukemia. 45. The compound of claim 1, wherein --N(R.sup.5)(R.sup.5') is morpholinyl; R.sup.2 is pyridine, pyridazine, pyrimidine, pyrazine, pyrole, oxazole, thiazole, furan or thiophene, in each case unsubstituted or substituted with 1, 2 or 3 R.sup.6 groups; and R.sup.3 is methyl. 46. The method of claim 42.Iadd., .Iaddend.wherein the cancer is colorectal cancer. 47. The compound of claim 1, wherein --N(R.sup.5)(R.sup.5') is morpholinyl; R.sup.2 is pyridine, pyridazine, pyrimidine, pyrazine, pyrole, oxazole, or thiazole, in each case unsubstituted or substituted with 1, 2 or 3 R.sup.6 groups; and R.sup.3 is methyl. .Iadd.48. The compound of claim 1 having the formula: ##STR00160## or a physiologically acceptable salt thereof, wherein: R.sup.2 is pyridine, pyridazine, pyrimidine, pyrazine, pyrole, oxazole or thiazole, in each case unsubstituted or substituted with 1, 2 or 3 R.sup.6 groups..Iaddend. .Iadd.49. The compound of claim 48, or a physiologically acceptable salt thereof, wherein: R.sup.2 is pyrimidine, substituted with one R.sup.6 group; R.sup.6 is --N(R.sup.7)(R.sup.7'); and R.sup.7 and R.sup.7' are each hydrogen..Iaddend. .Iadd.50. The compound of claim 49 having the formula: ##STR00161## or a physiologically acceptable salt thereof..Iaddend. .Iadd.51. A pharmaceutical composition comprising a compound according to claim 50 and a pharmaceutically acceptable diluent or carrier..Iaddend. .Iadd.52. A method of treating lymphoma in a mammal comprising administering to a mammal in need thereof, a therapeutically effective amount of a compound of claim 50..Iaddend. .Iadd.53. The compound according to claim 28, wherein said compound is selected from 2-amino-N-[7-methoxy-8-(3-morpholin-4-ylpropoxy)-2,3-dihydroimidazo[1,2-c- ]quinazolin-5-yl]pyrimidine-5-carboxamide and physiologically acceptable salts, solvates, hydrates and stereoisomers thereof..Iaddend. .Iadd.54. The compound according to claim 53, wherein said compound is 2-amino-N-[7-methoxy-8-(3-morpholin-4-ylpropoxy)-2,3-dihydroimidazo[1,2-c- ]quinazolin-5-yl]pyrimidine-5-carboxamide or a physiologically acceptable salt or hydrate thereof..Iaddend. .Iadd.55. A pharmaceutical composition comprising a compound according to claim 54, or a physiologically acceptable salt or hydrate thereof, and a pharmaceutically acceptable diluent or carrier..Iaddend. .Iadd.56. A method of treating lymphoma in a mammal comprising administering to a mammal in need thereof, a therapeutically effective amount of a compound of claim 54, or a physiologically acceptable salt or hydrate thereof..Iaddend. .Iadd.57. The compound of claim 50 having the formula: ##STR00162## .Iaddend.